TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22828247

Group type: EXPERIMENTAL
Intervention: Inspiratory loads (light: 8.4 cm H2O/L/s, moderate: 23.4 cm H2O/L/s, severe: 70.5 cm H2O/L/s) with deep breaths during normal breathing
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sudden removal of dyspnoea with a large increase in tidal volume (V(T))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of 'respiratory pleasure'
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Increase in tidal volume (V(T)) after removal of respiratory loading
Number of subjects: 35
Study: 20512042

Group type: EXPERIMENTAL
Intervention: Silexan (80 mg/day)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 18665826

Group type: EXPERIMENTAL
Intervention: 75 microg filgrastim
Number of subjects: 47

Group type: COMPARATOR
Intervention: 50 microg lenograstim
Number of subjects: 47
Study: 15942550

Group type: EXPERIMENTAL
Intervention: Oat bran cereal containing beta glucan (3 g daily)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Corn cereal without soluble fiber
Number of subjects: 152
Study: 12843352

Group type: EXPERIMENTAL
Intervention: Cross‐spectral analysis (CSA) in patients with high-degree M1 stenosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cross‐spectral analysis (CSA) in patients with low-degree M1 stenosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40
Study: 10770343

Group type: EXPERIMENTAL
Intervention: Topical alitretinoin 0.1% gel
Number of subjects: 268

Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Open-label alitretinoin treatment after blinded phase
Number of subjects: 268
Study: 8721798

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering treatments (specific types not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrate trials
Number of subjects: 0
Study: 1815423

Group type: EXPERIMENTAL
Intervention: Finger oscillometric blood pressure device
Number of subjects: 76

Group type: COMPARATOR
Intervention: Random-zero sphygmomanometer
Number of subjects: 76
Study: 6139422

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone releasing hormone (LHRH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31390654

Group type: EXPERIMENTAL
Intervention: Educational interventions in pathology education
Number of subjects: 54
Study: 29173829

Group type: EXPERIMENTAL
Intervention: Recruitment process by health care professionals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health care professionals' communication skills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of research designs
Number of subjects: 0
Study: 27009061

Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 25121977

Group type: EXPERIMENTAL
Intervention: Antidepressant cessation advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled data
Number of subjects: 0
Study: 20661161

Group type: EXPERIMENTAL
Intervention: Contrast baths
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ice baths
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no recovery)
Number of subjects: 26
Study: 19395584

Group type: EXPERIMENTAL
Intervention: CD-NP (novel chimeric natriuretic peptide)
Number of subjects: 0
Study: 17495560

Group type: EXPERIMENTAL
Intervention: Integrated medical and social care management model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purely social model
Number of subjects: 0
Study: 15491273

Group type: EXPERIMENTAL
Intervention: Faces of actors who performed trait-implying behaviors
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control faces (not specified in detail)
Number of subjects: 120
Study: 11208829

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (9 microg/kg/d)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (18 microg/kg/d)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (both doses)
Number of subjects: 71
Study: 9624068

Group type: EXPERIMENTAL
Intervention: Hospital at home care
Number of subjects: 486
Study: 7848401

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55% carbohydrates, 30% fats)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-monounsaturated-fat diet (40% carbohydrates, 45% fats)
Number of subjects: 42
Study: 3296163

Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin (C + G)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cefoxitin (Ce)
Number of subjects: 72
Study: 30307130

Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collagenated corticocancellous porcine bone (coll)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (ctrl)
Number of subjects: 90
Study: 27343780

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15mg) with 0.33% ropivacaine (30mL)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.33% ropivacaine (30mL) alone
Number of subjects: 53
Study: 24766166

Group type: EXPERIMENTAL
Intervention: Weekly telephone calls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both telephone calls and text messages
Number of subjects: 30
Study: 22321155

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) combined with exercise training (2 days a week)
Number of subjects: 30
Study: 20219265

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every other week)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 19010769

Group type: EXPERIMENTAL
Intervention: Intratumoural chemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 40
Study: 16160615

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d, mean dose at endpoint 8.75 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/d, mean dose at endpoint 2.88 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12893107

Group type: EXPERIMENTAL
Intervention: Short-term treatment of depression in patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy and/or psychopharmacologic treatment
Number of subjects: 0
Study: 10805839

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8857250

Group type: EXPERIMENTAL
Intervention: Chemiluminescent immunoassay (CLIA) for thyroid stimulating hormone (TSH) and free-T4
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Chemiluminescent immunoassay (CLIA) for intact-parathyroid hormone (PTH)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Combined CLIA for intact-PTH with serum calcium levels and clinical conditions
Number of subjects: 316

Group type: COMPARATOR
Intervention: Immunoradiometric immunoassay (IRMA) for TSH and PTH
Number of subjects: 316
Study: 1825315

Group type: EXPERIMENTAL
Intervention: HIV-1 infection preceding HBV infection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Unvaccinated HIV-1-infected persons
Number of subjects: 134

Group type: COMPARATOR
Intervention: HIV-1-infected persons who failed to respond to vaccination
Number of subjects: 134

Group type: COMPARATOR
Intervention: HIV-1-infected persons who received vaccine doses at the time of new HBV infection
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: HIV-1 infection
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Vaccinated HIV-1-negative men
Number of subjects: 134
Study: 6395212

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, vincristine, prednisone (CVP) chemotherapy with extended field radiotherapy (RT) in stage I patients.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Extended field radiotherapy (RT) in stage II patients.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Total nodal irradiation in stage II patients.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: New therapeutic strategy with alternating RT and CT tested in a pilot study.
Number of subjects: 180
Study: 31722952

Group type: EXPERIMENTAL
Intervention: My Breathing Matters (MBM) digital self-management intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study: 29415576

Group type: EXPERIMENTAL
Intervention: History of childhood sexual abuse
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Low religious participation
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1181
Study: 26704625

Group type: EXPERIMENTAL
Intervention: Fish before rice (FR)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Meat before rice (MR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rice before fish (RF)
Number of subjects: 22
Study: 25315941

Group type: EXPERIMENTAL
Intervention: Icy normal saline group (1,000 mL of 4°C normal saline intravenously)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (ice bag on head)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Icy normal saline group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 22305917

Group type: EXPERIMENTAL
Intervention: 400-mcg buccal misoprostol
Number of subjects: 1122

Group type: COMPARATOR
Intervention: 800-mcg buccal misoprostol
Number of subjects: 1122
Study: 21142988

Group type: EXPERIMENTAL
Intervention: VR-based orientation approach
Number of subjects: 54

Group type: COMPARATOR
Intervention: Text-based electronic information sheets
Number of subjects: 54
Study: 17962589

Group type: EXPERIMENTAL
Intervention: >=50% LDL-C reduction
Number of subjects: 4731

Group type: COMPARATOR
Intervention: No change or increase in LDL-C
Number of subjects: 4731
Study: 15691349

Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg tablets, twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (0.1% mouth rinse)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (negative control mouth rinse)
Number of subjects: 11
Study: 14569174

Group type: EXPERIMENTAL
Intervention: F0 test
Number of subjects: 36

Group type: COMPARATOR
Intervention: F+20 test
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PM image
Number of subjects: 36
Study: 10652038

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (KMgCit; 42 mEq K, 21 mEq Mg, and 63 mEq citrate/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Potassium chloride (42 mEq/day)
Number of subjects: 60
Study: 8882672

Group type: EXPERIMENTAL
Intervention: Triple session intervention
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Single session intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 318
Study: 1944425

Group type: EXPERIMENTAL
Intervention: 40 mg of oral milrinone daily
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 6494106

Group type: EXPERIMENTAL
Intervention: Weight-loss intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Na:K intervention
Number of subjects: 52
Study: 29688772

Group type: EXPERIMENTAL
Intervention: Scripted lesson plans and supporting activities as part of the revised sexuality education curriculum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study: 28511642

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Walk@WorkSpain (W@WS) program, n = 129 (87 female)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Active Comparison Group (A-CG) - pedometer, paper diary, and self-reported sitting time, n = 135 (84 female)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 264
Study: 26346122

Group type: EXPERIMENTAL
Intervention: Protocol B (hyaluronic acid injection + low-level laser therapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Protocol A (sham light source + saline injection)
Number of subjects: 70
Study: 23707331

Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) 500 mg capsule twice daily for nine weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21912062

Group type: EXPERIMENTAL
Intervention: Albendazole therapy for 12 weeks preoperatively and 12 weeks postoperatively
Number of subjects: 72

Group type: COMPARATOR
Intervention: No preoperative albendazole therapy (control group)
Number of subjects: 72
Study: 18257813

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (various dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16618292

Group type: EXPERIMENTAL
Intervention: Femoral pulse palpation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brachial pulse palpation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carotid pulse palpation
Number of subjects: 40
Study: 12945071

Group type: EXPERIMENTAL
Intervention: Cox-2 inhibitors
Number of subjects: 0
Study: 10901741

Group type: EXPERIMENTAL
Intervention: Stereotactic core needle biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-conserving approach
Number of subjects: 0
Study: 8884409

Group type: EXPERIMENTAL
Intervention: Hemostatic pause sequence (1.5 min inactivity with gauze swabs)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No pause sequence (no inactivity period)
Number of subjects: 101
Study: 1428568

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: betaxolol
Number of subjects: 8
Study: 6722065

Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol and norethisterone acetate (Group A, n = 22)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol plus oestriol and norethisterone acetate (Group B, n = 20)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (Group C, n = 23)
Number of subjects: 69
Study: 31207169

Group type: EXPERIMENTAL
Intervention: Fasinumab (1 mg, 3 mg, 6 mg, or 9 mg) every 4 weeks for 16 weeks
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Fasinumab
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Fasinumab (6 mg)
Number of subjects: 421
Study: 29944580

Group type: EXPERIMENTAL
Intervention: Carnoy's solution
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Revision group (formalin specimens immersed in Carnoy's solution)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Formalin
Number of subjects: 130
Study: 26084569

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no resistance training)
Number of subjects: 36
Study: 24767264

Group type: EXPERIMENTAL
Intervention: PNEIMED training (30 h over four days)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PNEIMED training
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-meditating control group
Number of subjects: 125
Study: 23131368

Group type: EXPERIMENTAL
Intervention: Integrative intervention of acupressure and interactive multimedia of visual health instruction (ACIMU)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AC) alone
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 287
Study: 20678893

Group type: EXPERIMENTAL
Intervention: Heated patch (lidocaine 70 mg/tetracaine 70 mg)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Unheated patch (lidocaine 70 mg/tetracaine 70 mg)
Number of subjects: 250
Study: 17885347

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 346
Study: 15844579

Group type: EXPERIMENTAL
Intervention: BCG‐SPN intramuscular injection (1ml, once every two days for 5 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Corticosteroid nasal spray (once a day for 5 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of BCG‐SPN and corticosteroid nasal spray (as above for 5 weeks)
Number of subjects: 96
Study: 12460131

Group type: EXPERIMENTAL
Intervention: Outpatient treatment approaches (5 types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient drug-free programs for adults (previous DATCAP results)
Number of subjects: 0
Study: 9799979

Group type: EXPERIMENTAL
Intervention: 75 micrograms clonidine intraspinally
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine intraspinally
Number of subjects: 45

Group type: COMPARATOR
Intervention: 80 mg mepivacaine 4% only
Number of subjects: 45
Study: 7648654

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rTPA)
Number of subjects: 1043

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: rTPA with immediate PTCA
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: rTPA without additional intervention
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: comparative rTPA group
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: rTPA and immediate PTCA
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: rTPA group without PTCA
Number of subjects: 1043
Study: 2503375

Group type: EXPERIMENTAL
Intervention: alfentanil and thiopentone for induction, followed by alfentanil‐N2O/O2 (60%/40%) for maintenance
Number of subjects: 40

Group type: COMPARATOR
Intervention: enflurane‐N2O/O2 (60%/40%) for maintenance
Number of subjects: 40
Study: 358713

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 U) administered 2 hours before surgery and every 8 hours for 6 days.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo injections administered to 47 operated patients.
Number of subjects: 144
Study: 30489119

Group type: EXPERIMENTAL
Intervention: act-extraverted intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: sham (active control) intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: contact control condition
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: dispositional extraversion
Number of subjects: 147
Study: 28100253

Group type: EXPERIMENTAL
Intervention: MIPO
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 64
Study: 25034442

Group type: EXPERIMENTAL
Intervention: Oleogel-S10 ointment containing 10% birch bark extract
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (intraindividual control, untreated half of the wound)
Number of subjects: 24
Study: 23934375

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stockings
Number of subjects: 70

Group type: COMPARATOR
Intervention: Short-stretch bandages
Number of subjects: 70
Study: 20927554

Group type: EXPERIMENTAL
Intervention: Deferred preemptive lamivudine upon viremic surge (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prophylactic lamivudine (Group 2)
Number of subjects: 45
Study: 19559142

Group type: EXPERIMENTAL
Intervention: Online calcium quiz
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Printed calcium food frequency questionnaire
Number of subjects: 140

Group type: COMPARATOR
Intervention: 3-day diet record
Number of subjects: 140
Study: 17348463

Group type: EXPERIMENTAL
Intervention: Clopidogrel (as a second antiplatelet drug)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard therapy without clopidogrel
Number of subjects: 65
Study: 15968162

Group type: EXPERIMENTAL
Intervention: Antireflection (AR) film on displays
Number of subjects: 7

Group type: COMPARATOR
Intervention: No antireflection (AR) film on displays
Number of subjects: 7
Study: 11771654

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (any dose)
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 9829138

Group type: EXPERIMENTAL
Intervention: 11-visit treatment program
Number of subjects: 162
Study: 8135557

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.15 mg/kg every 30 minutes for the first three hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Salbutamol (5 mg every one to four hours as needed)
Number of subjects: 70
Study: 2683917

Group type: EXPERIMENTAL
Intervention: Experimental group physicians attended a 2-hour multimedia educational session and received four functional status reports on each of their study patients over a 1-year period.
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group physicians received no education and no functional status feedback.
Number of subjects: 510
Study: 4941924

Group type: EXPERIMENTAL
Intervention: Intermittent compression of the lower limb during surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (uncompressed legs)
Number of subjects: 39
Study: 31848211

Group type: EXPERIMENTAL
Intervention: Core outcomes for age-related macular degeneration trials
Number of subjects: 301
Study: 30269924

Group type: EXPERIMENTAL
Intervention: Periocular triamcinolone acetonide (PTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (ITA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IDI)
Number of subjects: 0
Study: 28449205

Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative care (pharmacist-involved)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 411
Study: 26241433

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg per day
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Low-dose oral 17-beta-estradiol (E2) 0.5 mg per day
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Low-dose venlafaxine XR 75 mg per day
Number of subjects: 899

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 899

Group type: COMPARATOR
Intervention: Nonaerobic yoga
Number of subjects: 899

Group type: COMPARATOR
Intervention: Omega-3 fatty acid supplementation 1.8 g per day
Number of subjects: 899